BORVIZ 2MG contain Bortezomib which belongs to a group of medicine called proteasome inhibitor. Proteasomes plays an important role in controlling cell function and growth. By interfering with their function, it can kill cancer cells. It is used to treat multiple myeloma (a cancer of the bone marrow) and mantle cell lymphoma (a type of cancer affecting the lymph nodes) in patients 18 years or older.
Multiple myeloma is a cancer of plasma cells (a type of white blood cell in the bone marrow). In this condition, a group of plasma cell becomes cancerous and multiplies causing damage to the bone, immune system, kidney, and red blood cell count. It is also called as kahler's disease. Mantle cell lymphoma develops when B-cell (also called B-lymphocyte) become abnormal. B-cell are white blood cell that fight infection. The abnormal B-cell (lymphoma cell) usually build up in lymph nodes, but they can affect other parts of the body.
BORVIZ 2MG will be given to you by a doctor or nurse. It is intended to be administered by intravenous or subcutaneous. It is strictly not recommended for use in children and adolescents under 18 years. Before taking this medicine tell your doctor if you have ever had kidney disease, heart disease, liver problems. Pregnant and breastfeeding women should consult their doctor before taking this medicine. The most common side effects are nausea, vomiting, loss of appetite, constipation, with or without bloating, diarrhoea, tiredness (fatigue), feeling weak or loss of consciousness, muscle pain, bone pain, low or high blood pressure, reduced kidney function, headache and shivering.